OraSure Technologies, Inc.
Based in Bethlehem, Pennsylvania USA, OraSure Technologies develops, manufactures and markets point-of-care, oral fluid specimen collection devices that leverage proprietary oral fluid technologies, diagnostic products, including immunoassays and other in vitro diagnostic tests, and other medical devices.
These products include tests for the detection of antibodies for the HIV virus, including OraQuick ADVANCE Rapid HIV-1/2 Antibody Test and the OraSure HIV-1 Oral Specimen Collection Device, and oral fluid testing solutions for drugs of abuse testing, including Intercept Oral Fluid Drug Testing System and Q.E.D. Saliva Alcohol Test.
These products are sold in the United States, as well as internationally, to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities.
The Company also manufactures and sells several leading cryosurgical products. These include: Histofreezer, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market in the United States and many foreign countries. The Company also manufactures and sells an over-the-counter product for the cryosurgical removal of common and plantar warts, available in the United States, Canada, Mexico, certain European countries, Australia and New Zealand.
Web site: OraSure Technologies, Inc.
Founded at Paris University in 2002, BioPredictive is focused on the study, design and development of medically important biological tests. At the center of the company's scientific efforts is the desire to improve disease management by replacing invasive strategies with noninvasive alternatives. The objective of BioPredictive is to discover and develop non-invasive diagnostic tests in order to facilitate the management and treatment of patients.
BioPredictive has developed two noninvasive tests for chronic liver disease - FibroTest and ActiTest. FibroTest is a biochemical marker of liver fibrosis and ActiTest is a biochemical marker of inflammation and necrosis of the liver. After the launch of FibroTest-ActiTest in 2002, which has since become the reference standard of non-invasive diagnostic tests, BioPredictive continues to innovate with the new tests, SteatoTest, NashTest, AshTest and FibroMax. BioPredictive licenses the FibroTest and ActiTest technology from Assistance Public-Hopitaux de Paris (AP-HP).
The company performs several thousand tests per month, and services numerous private and public hospital laboratories in Europe, Africa, North and South America and Asia. To learn more about BioPredictive, visit the company Web site at: http://www.BioPredictive.com.
Augurix was established in 2006 by a dedicated group of professionals matching their skills in medicine, immunology and manufacturing.
About 30 years ago, Cecile was diagnosed with celiac disease. At this time, it was thought to be a rare condition, affecting mainly children. Little knowledge existed, besides the relation to the protein present in most cereals: gluten. Avoiding presence of gluten was - and still is - the only way to heal from the disease. Following the advice of a pediatrician, she logically started to apply a strict diet free of gluten.
In 2003, Cecile is a pediatrician herself and she is also mother of three. At the age of 18 months, her second son starts to present the same symptoms. Fortunately, the understanding of the disease has much evolved in 30 years: one knows now that the true prevalence is about 1% of the population, and finding gluten-free food is much easier than before.
However, the diagnostic process remains relatively long and tedious.Leveraging her personal experience as a patient, mother and doctor, Cecile starts Augurix in 2006 with her husband Thierry and her father Jean-Pierre. Their vision is to provide anyone with better tools to screen, diagnose and monitor Celiac Disease and its associated conditions.
Augurix is privately held.